MACK News and Press, Merrimack Pharmaceuticals Inc. From 05/30/19

Merrimack Pharmaceuticals (NASDAQ: MACK ) is 2.6% lower in postmarket trading after the company says it wrapped a strategic review by deciding not to move forward with a sale . More news on: Merrimack Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Merger & acquis...

CAMBRIDGE, Mass. , May 30, 2019 /PRNewswire/ --   Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced the completion of its review of strategic alternatives, following which the Company's Board of Directors is implementing a series of measures designed to extend Merrimack'...

Merrimack Pharmaceuticals (NASDAQ: MACK ): Q1 GAAP EPS of -$0.78. More news on: Merrimack Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

CAMBRIDGE, Mass. , May 10, 2019 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), an oncology company focused on biomarker-defined cancers, today announced its first quarter 2019 financial results for the period ended March 31, 2019 . "We continue to focus our efforts on ...

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...

Gainers:  Vital Therapies (NASDAQ: VTL ) +199% . JMU Limited (NASDAQ: JMU ) +24% . Aehr Test Systems (NASDAQ: AEHR ) +22% . GEE Group (NYSEMKT: JOB ) +19% . ChinaNet Online Holdings (NASDAQ: CNET ) +15% . RumbleON (NASDAQ: RMBL ) +15% . Hancock Jaffe Laboratories (NASDAQ: HJLI )...

AquaBounty Technologies (NASDAQ: AQB )  -23%  on pricing stock offering. More news on: AquaBounty Technologies, Inc., Duluth Holdings Inc., Merrimack Pharmaceuticals, Inc., Stocks on the move, Read more ...

CAMBRIDGE, Mass. , April 4, 2019 /PRNewswire/ --   Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), an oncology company focused on biomarker-defined cancers, today announced the Company is discontinuing development of MM-310, its antibody-directed nanotherapeutic for the treatment of ...

Merrimack Pharmaceuticals (NASDAQ: MACK ): FY GAAP EPS of -$4.55. More news on: Merrimack Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, , Read more ...